Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

COPD and Diabetes Mellitus: Down the Rabbit Hole

Author(s): Serghei Covantsev*, Olga Corlateanu, Stanislav I. Volkov, Rasul Uzdenov, Victor Botnaru and Alexandru Corlateanu

Volume 18, Issue 2, 2022

Published on: 27 May, 2022

Page: [95 - 103] Pages: 9

DOI: 10.2174/1573398X18666220411123508

Price: $65

Abstract

One of the important comorbidities that has a longstanding research history in COPD is diabetes. Although there are multiple studies on COPD and diabetes, the exact links between these two conditions are still controversial. The exact prevalence of diabetes in COPD varies between 2 and 37 %. The true nature of this relationship is complex and may be partially related to the traditional risk factors for diabetes such as smoking, cardiovascular disease and use of steroids. However, COPD is a disease that has multiple phenotypes and is no longer regarded as a homogeneous condition. It seems that some COPD patients who overlap with asthma or the obese phenotype are at a particular risk for T2DM. The aim of this review is to analyze the prevalence, risk factors and possible interactions between COPD and diabetes mellitus.

Keywords: Asthma-COPD overlap, COPD, diabetes mellitus, glycated hemoglobin, glucose variability, comorbidities, smoking, lung cancer.

« Previous Next »
Graphical Abstract

[1]
Devine JF. Chronic obstructive pulmonary disease: An overview. Am Health Drug Benefits 2008; 1(7): 34-42.
[PMID: 25126252]
[2]
Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pul-monary disease. Respir Investig 2016; 54(6): 387-96.
[http://dx.doi.org/10.1016/j.resinv.2016.07.001] [PMID: 27886849]
[3]
Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med 2015; 10(1): 24.
[http://dx.doi.org/10.1186/s40248-015-0023-2] [PMID: 26246895]
[4]
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33(5): 1165-85.
[http://dx.doi.org/10.1183/09031936.00128008] [PMID: 19407051]
[5]
Rogliani P, Lucà G, Lauro D. Chronic obstructive pulmonary disease and diabetes. COPD Res Prac 2015; 1(1): 3.
[http://dx.doi.org/10.1186/s40749-015-0005-y]
[6]
Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: A bitter sweet symphony. Cardiovasc Diabetol 2012; 11(1): 132.
[http://dx.doi.org/10.1186/1475-2840-11-132] [PMID: 23101436]
[7]
Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003; 41(41)(Suppl.): 29s-35s.
[http://dx.doi.org/10.1183/09031936.03.00078203] [PMID: 12795329]
[8]
Barnes PJ. Chronic obstructive pulmonary disease: A growing but neglected global epidemic. PLoS Med 2007; 4(5): e112.
[http://dx.doi.org/10.1371/journal.pmed.0040112] [PMID: 17503959]
[9]
Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27(2): 397-412.
[http://dx.doi.org/10.1183/09031936.06.00025805] [PMID: 16452599]
[10]
Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary dis-ease: Systematic review and meta-analysis. East Mediterr Health J 2019; 25(1): 47-57.
[http://dx.doi.org/10.26719/emhj.18.014]
[11]
Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12(7): 703-8.
[12]
Menezes AM, Perez-Padilla R, Hallal PC, et al. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: The PLATINO study. Int J Tuberc Lung Dis 2008; 12(7): 709-12.
[13]
Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003; 45(5): 405-13.
[http://dx.doi.org/10.1016/S0033-0620(03)80004-X] [PMID: 12704597]
[14]
Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: Dangerous liaisons and confusing relationships. Diabetol Metab Syndr 2019; 11(1): 85.
[http://dx.doi.org/10.1186/s13098-019-0482-2] [PMID: 31666811]
[15]
Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): A systematic literature review. Int J Chron Obstruct Pulmon Dis 2020; 15: 439-60.
[http://dx.doi.org/10.2147/COPD.S234942] [PMID: 32161455]
[16]
Guan WJ, Han XR, de la Rosa-Carrillo D, Martinez-Garcia MA. The significant global economic burden of bronchiectasis: A pending mat-ter. Eur Respir J 2019; 53(2): 1802392.
[http://dx.doi.org/10.1183/13993003.02392-2018] [PMID: 30819807]
[17]
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
[http://dx.doi.org/10.1016/j.diabres.2017.03.024] [PMID: 28437734]
[18]
The diabetes pandemic. Lancet 2011; 378(9786): 99.
[http://dx.doi.org/10.1016/S0140-6736(11)61068-4] [PMID: 21742159]
[19]
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87(1): 4-14.
[http://dx.doi.org/10.1016/j.diabres.2009.10.007] [PMID: 19896746]
[20]
Meteran H, Backer V, Kyvik KO, Skytthe A, Thomsen SF. Comorbidity between chronic obstructive pulmonary disease and type 2 diabe-tes: A nation-wide cohort twin study. Respir Med 2015; 109(8): 1026-30.
[http://dx.doi.org/10.1016/j.rmed.2015.05.015] [PMID: 26044811]
[21]
Hersh CP, Make BJ, Lynch DA, et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med 2014; 14(1): 164.
[http://dx.doi.org/10.1186/1471-2466-14-164] [PMID: 25341556]
[22]
Crisafulli E, Torres A, Huerta A, et al. C-reactive protein at discharge, diabetes mellitus and ≥ 1 hospitalization during previous year pre-dict early readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. COPD 2015; 12(3): 306-14.
[http://dx.doi.org/10.3109/15412555.2014.933954] [PMID: 25279441]
[23]
Habib G, Dar-Esaif Y, Bishara H, et al. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 dia-betes with chronic obstructive pulmonary disease exacerbation. Respir Med 2014; 108(11): 1641-6.
[http://dx.doi.org/10.1016/j.rmed.2014.08.006] [PMID: 25192601]
[24]
Li CI, Li TC, Liu CS, et al. Extreme values of hemoglobin a1c are associated with increased risks of chronic obstructive pulmonary dis-ease in patients with type 2 diabetes: A competing risk analysis in national cohort of Taiwan diabetes study. Medicine (Baltimore) 2015; 94(1): e367.
[http://dx.doi.org/10.1097/MD.0000000000000367] [PMID: 25569658]
[25]
Rambaran K, Bhagan B, Ali A, et al. High prevalence of diabetes mellitus in a cohort of patients with chronic obstructive pulmonary dis-ease in Trinidad, West Indies. Turk Thorac J 2019; 20(1): 12-7.
[http://dx.doi.org/10.5152/TurkThoracJ.2018.18036] [PMID: 30664421]
[26]
Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol 2014; 51(6): 933-40.
[http://dx.doi.org/10.1007/s00592-014-0584-0] [PMID: 24728837]
[27]
Ajmera M, Shen C, Sambamoorthi U. Concomitant medication use and new-onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease. Popul Health Manag 2017; 20(3): 224-32.
[http://dx.doi.org/10.1089/pop.2016.0047] [PMID: 27689453]
[28]
Price DB, Russell R, Mares R, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: A histori-cal matched cohort study. PLoS One 2016; 11(9): e0162903.
[http://dx.doi.org/10.1371/journal.pone.0162903] [PMID: 27658209]
[29]
Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: Impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36(10): 3009-14.
[http://dx.doi.org/10.2337/dc12-2197] [PMID: 23735725]
[30]
Wouters EF, Bredenbröker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in pa-tients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97(9): E1720-5.
[http://dx.doi.org/10.1210/jc.2011-2886] [PMID: 22723325]
[31]
Terzano C, Colamesta V, Unim B, et al. Chronic obstructive pulmonary disease (COPD) exacerbation: Impact of comorbidities on length and costs during hospitalization. Eur Rev Med Pharmacol Sci 2017; 21(16): 3680-9.
[PMID: 28925473]
[32]
Ho T-W, Huang C-T, Ruan S-Y, Tsai Y-J, Lai F, Yu C-J. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS One 2017; 12(4): e0175794.
[http://dx.doi.org/10.1371/journal.pone.0175794] [PMID: 28410410]
[33]
Corlateanu A, Stratan I, Covantev S, Botnaru V, Corlateanu O, Siafakas N. Asthma and stroke: A narrative review. Asthma Res Pract 2021; 7(1): 3.
[http://dx.doi.org/10.1186/s40733-021-00069-x] [PMID: 33608061]
[34]
Corlateanu A, Botnaru V, Sircu V, Covantev S, Montanari G. Obstructive sleep apnea and type 2 diabetes: Dual interaction. Curr Respir Med Rev 2015; 11(4): 292-8.
[http://dx.doi.org/10.2174/1573398X11666150915212520]
[35]
Balk-Møller E, Windeløv JA, Svendsen B, et al. Glucagon-like peptide 1 and atrial natriuretic peptide in a female mouse model of obstruc-tive pulmonary disease. J Endocr Soc 2019; 4(1): bvz034.
[http://dx.doi.org/10.1210/jendso/bvz034] [PMID: 32010874]
[36]
Rayner LH, McGovern AP, Sherlock J, et al. Type 2 diabetes: A protective factor for COPD? Prim Care Diabetes 2018; 12(5): 438-44.
[http://dx.doi.org/10.1016/j.pcd.2018.05.002] [PMID: 29843977]
[37]
Khalil MM, Mohammed RM, Hassan OHS. A study of the relationship between pulmonary function tests and both fasting plasma glucose and glycated hemoglobin levels among asymptomatic cigarette smokers. Egypt J Bronchol 2019; 13(4): 516-22.
[http://dx.doi.org/10.4103/ejb.ejb_36_19]
[38]
Papathanassiou E, Papaioannou AI, Papanikolaou I, et al. Glycated Hemoglobin (HbA1c) as a predictor of outcomes during acute exacer-bations of chronic obstructive pulmonary disease. COPD 2021; 18(2): 219-25.
[http://dx.doi.org/10.1080/15412555.2021.1902491] [PMID: 33759663]
[39]
Papathanassiou E, Papaioannou A, Hillas G, et al. Glycated hemoglobin (HbA1c) and acute exacerbation in chronic obstructive pulmonary disease: A potent biomarker of severity and prognosis. Preliminary data. Eur Respir J 2018; 52(Suppl. 62).: PA1079.
[40]
Badawy MS, Rashad AM, Elhabashy MM, Qasem RM. Evaluation of co-morbidities among different chronic obstructive pulmonary dis-ease phenotypes. Int J Thorax 2018; 1(1): 8.
[41]
Baba S, Takashima T, Hirota M, Kawashima M, Horikawa E. Relationship between pulmonary function and elevated glycated hemoglobin levels in health checkups: A cross-sectional observational study in Japanese participants. J Epidemiol 2017; 27(11): 511-5.
[http://dx.doi.org/10.1016/j.je.2016.10.008] [PMID: 28142050]
[42]
Chiu H-T, Li T-C, Li C-I, Liu C-S, Lin W-Y, Lin C-C. Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pul-monary disease in patients with type 2 diabetes mellitus: Competing risk analysis using a national cohort from the Taiwan diabetes study. PLoS One 2017; 12(5): e0177184.
[http://dx.doi.org/10.1371/journal.pone.0177184] [PMID: 28489885]
[43]
Gläser S, Krüger S, Merkel M, Bramlage P, Herth FJF. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. Respiration 2015; 89(3): 253-64.
[http://dx.doi.org/10.1159/000369863] [PMID: 25677307]
[44]
James BD, Jones AV, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: Is exercise the answer? Chron Respir Dis 2018; 15(2): 173-81.
[http://dx.doi.org/10.1177/1479972317736294] [PMID: 29117797]
[45]
Alahmari AD, Kowlessar BS, Patel AR, et al. Physical activity and exercise capacity in patients with moderate COPD exacerbations. Eur Respir J 2016; 48(2): 340-9.
[http://dx.doi.org/10.1183/13993003.01105-2015] [PMID: 27126688]
[46]
Singer J, Yelin EH, Katz PP, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: Impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev 2011; 31(2): 111-9.
[http://dx.doi.org/10.1097/HCR.0b013e3182033663] [PMID: 21240003]
[47]
Farooqi MAM, Killian K, Satia I. The impact of muscle strength on exercise capacity and symptoms. ERJ Open Res 2020; 6(4): 00089-2020.
[http://dx.doi.org/10.1183/23120541.00089-2020] [PMID: 33043042]
[48]
Daabis R, Hassan M, Zidan M. Endurance and strength training in pulmonary rehabilitation for COPD patients. Egypt J Chest Dis Tuberc 2017; 66(2): 231-6.
[http://dx.doi.org/10.1016/j.ejcdt.2016.07.003]
[49]
Arne M, Janson C, Janson S, et al. Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scand J Prim Health Care 2009; 27(3): 141-7.
[http://dx.doi.org/10.1080/02813430902808643] [PMID: 19306158]
[50]
Filley GF, Beckwitt HJ, Reeves JT, Mitchell RS. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med 1968; 44(1): 26-38.
[http://dx.doi.org/10.1016/0002-9343(68)90234-9] [PMID: 5635286]
[51]
Petty TL, Miercort R, Ryan S, Vincent T, Filley GF, Mitchell RS. The functional and bronchographic evaluation of postmortem human lungs. Am Rev Respir Dis 1965; 92: 450-8.
[PMID: 14346370]
[52]
Budnevsky AV, Ovsyannikov ES, Labzhania NB. Chronic obstructive pulmonary disease concurrent with metabolic syndrome: Patho-physiological and clinical features. Ter Arkh 2017; 89(1): 123-7.
[53]
Fuller-Thomson E, Howden KEN, Fuller-Thomson LR, Agbeyaka S. A Strong graded relationship between level of obesity and COPD: Findings from a national population-based study of lifelong nonsmokers. J Obes 2018; 2018: 6149263.
[http://dx.doi.org/10.1155/2018/6149263] [PMID: 30584475]
[54]
Wouters EFM. Obesity and metabolic abnormalities in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2017; 14(Suppl. 5): S389-94.
[http://dx.doi.org/10.1513/AnnalsATS.201705-371AW] [PMID: 29161076]
[55]
Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: A novel approach using principal component and cluster analyses. Eur Respir J 2010; 36(3): 531-9.
[http://dx.doi.org/10.1183/09031936.00175109] [PMID: 20075045]
[56]
Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 2012; 7(12): e51048.
[http://dx.doi.org/10.1371/journal.pone.0051048] [PMID: 23236428]
[57]
Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different progno-ses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015; 12(3): 303-12.
[http://dx.doi.org/10.1513/AnnalsATS.201403-125OC] [PMID: 25642832]
[58]
Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmo-nary disease (COPD) subtypes. Thorax 2011; 66(5): 430-7.
[http://dx.doi.org/10.1136/thx.2010.154484] [PMID: 21177668]
[59]
Verberne LDM, Leemrijse CJ, Swinkels ICS, van Dijk CE, de Bakker DH, Nielen MMJ. Overweight in patients with chronic obstructive pulmonary disease needs more attention: A cross-sectional study in general practice. NPJ Prim Care Respir Med 2017; 27(1): 63.
[http://dx.doi.org/10.1038/s41533-017-0065-3] [PMID: 29167434]
[60]
Zheng X, Zheng X, Wang X, et al. Acute hypoxia induces apoptosis of pancreatic β-cell by activation of the unfolded protein response and upregulation of CHOP. Cell Death Dis 2012; 3(6): e322.
[http://dx.doi.org/10.1038/cddis.2012.66]
[61]
Hjalmarsen A, Aasebø U, Birkeland K, Sager G, Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996; 22(1): 37-42.
[PMID: 8697294]
[62]
Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B. Oxygen therapy for patients with COPD: Current evidence and the long-term oxygen treatment trial. Chest 2010; 138(1): 179-87.
[http://dx.doi.org/10.1378/chest.09-2555] [PMID: 20605816]
[63]
Hajizadeh N, Goldfeld K, Crothers K. What happens to patients with COPD with long-term oxygen treatment who receive mechanical ven-tilation for COPD exacerbation? A 1-year retrospective follow-up study. Thorax 2015; 70(3): 294-6.
[http://dx.doi.org/10.1136/thoraxjnl-2014-205248] [PMID: 24826845]
[64]
Owens RL, Malhotra A. Sleep-disordered breathing and COPD: The overlap syndrome. Respir Care 2010; 55(10): 1333-44.
[PMID: 20875160]
[65]
McNicholas WT. COPD-OSA overlap syndrome: Evolving evidence regarding epidemiology, clinical consequences, and management. Chest 2017; 152(6): 1318-26.
[http://dx.doi.org/10.1016/j.chest.2017.04.160] [PMID: 28442310]
[66]
Zozina VI, Covantev S, Kukes VG, Corlateanu A. Coenzyme Q10 in COPD: An Unexplored Opportunity? COPD 2021; 18(1): 114-22.
[http://dx.doi.org/10.1080/15412555.2020.1849084] [PMID: 33441012]
[67]
Marinari S, Manigrasso MR, De Benedetto F. Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Ter multicomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. Multidiscip Respir Med 2013; 8(1): 40.
[http://dx.doi.org/10.1186/2049-6958-8-40] [PMID: 23800154]
[68]
Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107(9): 1376-84.
[http://dx.doi.org/10.1016/j.rmed.2013.05.001] [PMID: 23791463]
[69]
Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: A prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis 2012; 7: 571-6.
[PMID: 23055707]
[70]
Mahishale V, Avuthu S, Patil B, Lolly M, Eti A, Khan S. Effect of poor glycemic control in newly diagnosed patients with smear-positive pulmonary tuberculosis and type-2 diabetes mellitus. Iran J Med Sci 2017; 42(2): 144-51.
[PMID: 28360440]
[71]
Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010; 15(6): 918-22.
[http://dx.doi.org/10.1111/j.1440-1843.2010.01781.x] [PMID: 20546185]
[72]
Mao X, Liang C, Niu H, et al. Outcomes associated with comorbid diabetes among patients with COPD exacerbation: Findings from the ACURE registry. Respir Res 2021; 22(1): 7.
[http://dx.doi.org/10.1186/s12931-020-01607-6] [PMID: 33407433]
[73]
Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61(4): 284-9.
[http://dx.doi.org/10.1136/thx.2005.051029] [PMID: 16449265]
[74]
Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH. Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ 2013; 112(6): 244-9.
[PMID: 24511864]
[75]
Ceriello A. Glucose variability and diabetic complications: Is it time to treat? Diabetes Care 2020; 43(6): 1169-71.
[http://dx.doi.org/10.2337/dci20-0012] [PMID: 32434893]
[76]
Wang M-T, Lai J-H, Huang Y-L, et al. Use of antidiabetic medications and risk of chronic obstructive pulmonary disease exacerbation requiring hospitalization: A disease risk score-matched nested case-control study. Respir Res 2020; 21(1): 319.
[http://dx.doi.org/10.1186/s12931-020-01547-1] [PMID: 33267895]
[77]
Yen F-S, Chen W, Wei JC-C, Hsu C-C, Hwu C-M. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design. PLoS One 2018; 13(10): e0204859.
[http://dx.doi.org/10.1371/journal.pone.0204859] [PMID: 30286138]
[78]
Zhu A, Teng Y, Ge D, Zhang X, Hu M, Yao X. Role of metformin in treatment of patients with chronic obstructive pulmonary disease: A systematic review. J Thorac Dis 2019; 11(10): 4371-8.
[http://dx.doi.org/10.21037/jtd.2019.09.84] [PMID: 31737323]
[79]
Hitchings AW, Lai D, Jones PW, Baker EH. Metformin in severe exacerbations of chronic obstructive pulmonary disease: A randomised controlled trial. Thorax 2016; 71(7): 587-93.
[http://dx.doi.org/10.1136/thoraxjnl-2015-208035] [PMID: 26917577]
[80]
Ho T-W, Huang C-T, Tsai Y-J, Lien AS-Y, Lai F, Yu C-J. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res 2019; 20(1): 69.
[http://dx.doi.org/10.1186/s12931-019-1035-9] [PMID: 30953517]
[81]
Bishwakarma R, Zhang W, Lin Y-L, Kuo Y-F, Cardenas VJ, Sharma G. Metformin use and health care utilization in patients with coexist-ing chronic obstructive pulmonary disease and diabetes mellitus. Int J Chron Obstruct Pulmon Dis 2018; 13: 793-800.
[http://dx.doi.org/10.2147/COPD.S150047] [PMID: 29551895]
[82]
Yen F-S, Wei JC-C, Yang Y-C, Hsu C-C, Hwu C-M. Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. Sci Rep 2020; 10(1): 10298.
[http://dx.doi.org/10.1038/s41598-020-67338-2] [PMID: 32581289]
[83]
Chen K-Y, Chien L-N, Tseng C-H, Lee K-Y. Metformin predispose acute exacerbations of COPD patients with insulin-dependent diabetes mellitus. Eur Respir J 2018; 52(Suppl. 62).: PA4027.
[84]
Tseng CH. Metformin and risk of chronic obstructive pulmonary disease in diabetes patients. Diabetes Metab 2019; 45(2): 184-90.
[http://dx.doi.org/10.1016/j.diabet.2018.05.001] [PMID: 29804817]
[85]
Filion KB, Douros A, Azoulay L, Yin H, Yu OH, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. Br J Clin Pharmacol 2019; 85(10): 2378-89.
[http://dx.doi.org/10.1111/bcp.14056] [PMID: 31276600]
[86]
Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Cazzola M, Siafakas N. Chronic obstructive pulmonary disease and stroke. COPD 2018; 15(4): 405-13.
[http://dx.doi.org/10.1080/15412555.2018.1464551] [PMID: 29746193]
[87]
Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharmacologic differences of sulfonylureas and the risk of adverse cardio-vascular and hypoglycemic events. Diabetes Care 2017; 40(11): 1506-13.
[http://dx.doi.org/10.2337/dc17-0595] [PMID: 28864502]
[88]
Rinne ST, Liu C-F, Feemster LC, et al. Thiazolidinediones are associated with a reduced risk of COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2015; 10: 1591-7.
[http://dx.doi.org/10.2147/COPD.S82643] [PMID: 26300638]
[89]
Chen K-Y, Wu S-M, Tseng C-H, et al. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerba-tions in new-onset COPD patients with advanced diabetic mellitus: A cohort-based case-control study. BMC Pulm Med 2021; 21(1): 141.
[http://dx.doi.org/10.1186/s12890-021-01505-7] [PMID: 33926423]
[90]
Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infec-tion: Systematic review and meta-analysis. Thorax 2011; 66(5): 383-8.
[http://dx.doi.org/10.1136/thx.2010.152777] [PMID: 21325145]
[91]
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2004; 27(1): 256-63.
[92]
Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121(16): 1868-77.
[http://dx.doi.org/10.1161/CIR.0b013e3181d34114] [PMID: 20179252]
[93]
Viby N-E, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and im-proves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology 2013; 154(12): 4503-11.
[http://dx.doi.org/10.1210/en.2013-1666] [PMID: 24092637]
[94]
Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Ashtma-Chronic obstructive pulmonary disease overlap syndrome (ACOS): Current evidence and future research directions. COPD Res Prac 2017; 3(1): 6.
[http://dx.doi.org/10.1186/s40749-017-0025-x]
[95]
Nielsen M, Bårnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome-a systematic review. Int J Chron Obstruct Pulmon Dis 2015; 10: 1443-54.
[PMID: 26251584]
[96]
Brzostek D, Kokot M. Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study. Postepy Dermatol Alergol 2014; 31(6): 372-9.
[http://dx.doi.org/10.5114/pdia.2014.47120] [PMID: 25610352]
[97]
Wu TD, Fawzy A, Kinney GL, et al. Metformin use and respiratory outcomes in asthma-COPD overlap. Respir Res 2021; 22(1): 70.
[http://dx.doi.org/10.1186/s12931-021-01658-3] [PMID: 33637087]
[98]
Koleade A, Farrell J, Mugford G, Gao Z. Prevalence and Risk Factors of ACO (Asthma-COPD Overlap) in Aboriginal People. J Environ Public Health 2018; 2018: 4657420.
[http://dx.doi.org/10.1155/2018/4657420] [PMID: 30584428]
[99]
Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33(1): 55-60.
[http://dx.doi.org/10.2337/dc09-0880] [PMID: 19808918]
[100]
Shen T-C, Chung W-S, Lin C-L, et al. Does chronic obstructive pulmonary disease with or without type 2 diabetes mellitus influence the risk of lung cancer? Result from a population-based cohort study. PLoS One 2014; 9(5): e98290.
[http://dx.doi.org/10.1371/journal.pone.0098290] [PMID: 24854189]
[101]
Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: A population-based observation in Taiwan. Clin Lung Cancer 2012; 13(2): 143-8.
[http://dx.doi.org/10.1016/j.cllc.2011.10.002] [PMID: 22129971]
[102]
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstruc-tive pulmonary disease. N Engl J Med 2004; 350(10): 1005-12.
[http://dx.doi.org/10.1056/NEJMoa021322] [PMID: 14999112]
[103]
Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med 2009; 103(5): 692-9.
[http://dx.doi.org/10.1016/j.rmed.2008.12.005] [PMID: 19131231]
[104]
Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predic-tive of mortality in COPD. Prim Care Respir J 2012; 21(3): 295-301.
[105]
Puhan MA, Hansel NN, Sobradillo P, et al. Large-scale international validation of the ADO index in subjects with COPD: An individual subject data analysis of 10 cohorts. BMJ Open 2012; 2(6): e002152.
[http://dx.doi.org/10.1136/bmjopen-2012-002152] [PMID: 23242246]
[106]
Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: The CODEX index. Chest 2014; 145(5): 972-80.
[http://dx.doi.org/10.1378/chest.13-1328] [PMID: 24077342]
[107]
Corlateanu A, Plahotniuc A, Corlateanu O, et al. Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respir Med 2021; 185: 106519.
[http://dx.doi.org/10.1016/j.rmed.2021.106519] [PMID: 34175803]
[108]
Gray N, Picone G, Sloan F, Yashkin A. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J 2015; 108(1): 29-36.
[http://dx.doi.org/10.14423/SMJ.0000000000000214] [PMID: 25580754]
[109]
Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs 2002; 16(2): 17-23.
[http://dx.doi.org/10.1097/00005082-200201000-00003] [PMID: 11800065]
[110]
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Develop-ment and validation. J Chronic Dis 1987; 40(5): 373-83.
[http://dx.doi.org/10.1016/0021-9681(87)90171-8] [PMID: 3558716]
[111]
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital dis-charge abstracts using data from 6 countries. Am J Epidemiol 2011; 173(6): 676-82.
[http://dx.doi.org/10.1093/aje/kwq433] [PMID: 21330339]
[112]
de Torres JP, Casanova C, Marín JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014; 69(9): 799-804.
[http://dx.doi.org/10.1136/thoraxjnl-2014-205770] [PMID: 24969641]
[113]
Stolz D, Louis R, Boersma W, et al. COPD-specific co-morbidity test (COTE) for predicting mortality in COPD - Results of an European, multicenter study. Eur Respir J 2014; 44(Suppl. 58): 566.
[114]
Tachkov K, Mitov K, Koleva Y, et al. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic popu-lation in Bulgaria. PLoS One 2020; 15(5): e0232815.
[http://dx.doi.org/10.1371/journal.pone.0232815] [PMID: 32392235]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy